Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.31 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30305561 | 1.00 | KDR (0.36) | KDRSLC6A2SLC6A4SLC6A3CSF1R | |
| SCHEMBL23984567 | 1.00 | KDR (0.36) | KDRSLC6A2SLC6A4SLC6A3CSF1R | |
| SCHEMBL30305516 | 1.00 | KDR (0.36) | KDRSLC6A2SLC6A4SLC6A3CSF1R | |
| SCHEMBL30305562 | 1.00 | KDR (0.36) | KDRSLC6A2SLC6A4SLC6A3CSF1R | |
| SCHEMBL30305451 | 1.00 | KDR (0.36) | KDRSLC6A2SLC6A4SLC6A3CSF1R | |
| SCHEMBL23984566 | 1.00 | KDR (0.36) | KDRSLC6A2SLC6A4SLC6A3CSF1R | |
| SCHEMBL23984644 | 0.95 | KDR (0.36) | KDRSLC6A2SLC6A4SLC6A3CSF1R | |
| SCHEMBL23984643 | 0.95 | KDR (0.36) | KDRSLC6A2SLC6A4SLC6A3CSF1R | |
| SCHEMBL23985535 | 0.93 | SLC6A2 (0.35) | KDRSLC6A2SLC6A4SLC6A3CSF1R | |
| SCHEMBL23984668 | 0.92 | BRAF (0.39) | KDRCSF1RJAK2ADCY8ADCY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RELAY THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | RELAY THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240287058-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023081757-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF MAKING AND USING THE SAME | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4143196-A1 | PI3K-a INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222556-A1 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222556-A1 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | PIK3CD, PIK3CB, PIK3R1 | KDR 1435/4885SLC6A2 3291/4885SLC6A4 3594/4885 |
| US-20240287058-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | KDR 1841/4885SLC6A2 4564/4885SLC6A4 4637/4885 |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RORB, ROR1, RORA | KDR 416/4885SLC6A2 2817/4885SLC6A4 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.